Research · Aug 25, 2026
Rare CNS Gene Therapy Moves Past Sham-Surgery Control
uniQure, ClearPoint and BioCardia disclosed the FDA no longer requires a sham-surgery control in rare CNS gene therapy, moving the gate to delivery hardware.
CYRX
Cryoport, Inc.
NASDAQ · Industrials · Integrated Freight & Logistics · US
$15.91
+0.32%